Steffen Thirstrup
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Steffen Thirstrup has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Bruno Sepodes
7 shared publicationsJuan Garcia Burgos
7 shared publications- Bruno Sepodes
Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
5 shared publications - Juan Garcia Burgos
Stakeholders and Communication Division European Medicines Agency Amsterdam The Netherlands
5 shared publications Emer Cooke
European Medicines Agency, Amsterdam, The Netherlands
2 shared publications- Frank Pétavy
European Medicines Agency Amsterdam The Netherlands
2 shared publications
Latest Publications
- 9 November 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 71
European Medicines Agency approvals of new medicines in September and October 2026
- 9 November 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 71
European Medicines Agency approvals of new medicines in September and October 2026
- 8 September 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 69
European Medicines Agency approvals of new medicines in July and August 2026
- 8 September 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 69
European Medicines Agency approvals of new medicines in July and August 2026
- 9 July 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 67
European Medicines Agency approvals of new medicines in May and June 2026
- 9 July 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 67
European Medicines Agency approvals of new medicines in May and June 2026
- 14 May 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 65
European Medicines Agency approvals of new medicines in March and April 2026
- 14 May 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 65
European Medicines Agency approvals of new medicines in March and April 2026
- 19 March 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 63
European medicines agency approvals of new medicines in January and February 2026
- 19 March 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 63
European medicines agency approvals of new medicines in January and February 2026
- Top Cited PapersOpen Access
- 10 March 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 63, 101644
Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab
- 10 March 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 63, 101644
Top Cited PapersOpen AccessBalancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab
- 8 January 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 61
European Medicines Agency approvals of new medicines in November and December 2025
- 8 January 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 61
European Medicines Agency approvals of new medicines in November and December 2025
- Open Access
- 26 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S3) , e107832
EMA perspective on Diagnosis of Alzheimer's
Background: Regulatory agencies approval of medicines is always associated with a guidance to the prescriber and patient on the correct use. This include among other a detailed description of the target indication, ie the population for which the product has been shown to have an acceptable benefit:risk ratio. The population of the approved target indication is reflected in the patient population in which the supporting clinical evidence has been generated, which then again is linked to the design and conduct of therapeutic confirmatory clinical trials. Method: Review of current EMA policy Results: Having globally agreed diagnostic criteria for a certain condition/disease is favouring global drug development and global regulatory alignment. Without such alignment clinical trials many have to be replicated or designed to meet different diagnostic criteria to meet regulatory expectations. Conclusion: This intervention will briefly outline the position of the European Medicines Agency on the above challenges with special attention to the current debate on diagnostic criteria for Alzheimer's Disease
- 26 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S3) , e107832
Open AccessEMA perspective on Diagnosis of Alzheimer's
Background: Regulatory agencies approval of medicines is always associated with a guidance to the prescriber and patient on the correct use. This include among other a detailed description of the target indication, ie the population for which the product has been shown to have an acceptable benefit:risk ratio. The population of the approved target indication is reflected in the patient population in which the supporting clinical evidence has been generated, which then again is linked to the design and conduct of therapeutic confirmatory clinical trials. Method: Review of current EMA policy Results: Having globally agreed diagnostic criteria for a certain condition/disease is favouring global drug development and global regulatory alignment. Without such alignment clinical trials many have to be replicated or designed to meet different diagnostic criteria to meet regulatory expectations. Conclusion: This intervention will briefly outline the position of the European Medicines Agency on the above challenges with special attention to the current debate on diagnostic criteria for Alzheimer's Disease
- 21 November 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 59
European Medicines Agency approvals of new medicines in September and October 2025
- 21 November 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 59
European Medicines Agency approvals of new medicines in September and October 2025
- Open Access
- 28 October 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (6) , 1392-1404
A Fast Path from Innovation to Safe and Effective Medicines
Consistent progress in medicines development has allowed both for de novo treatment options and for the refinement of existing products that improve effectiveness or reduce harm. Nonetheless, unmet medical needs persist, particularly in rare diseases, pediatrics and underserved populations. The many promises of pharmacological, technological, and regulatory innovation spark new hope for patients and doctors searching for treatments, and it is therefore essential that progress made translates into the availability of new and improved medicines. We here present our vision for accelerating the path from innovation to safe and effective medicines. Our vision is driven by the continued and transparent collaboration between regulators, academia, industry, patients, and healthcare professionals. Through concrete examples and strategic initiatives, we illustrate how the EMA works with stakeholders to support continuous evolution of regulatory science, contribute to patient‐focused refinements in evidence generation and medicines assessments, and engage in forward‐looking initiatives that monitor and examine innovative developments. The ultimate goal is to future‐proof the regulatory ecosystem and ensure that scientific progress translates into meaningful health outcomes.
- 28 October 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (6) , 1392-1404
Open AccessA Fast Path from Innovation to Safe and Effective Medicines
Consistent progress in medicines development has allowed both for de novo treatment options and for the refinement of existing products that improve effectiveness or reduce harm. Nonetheless, unmet medical needs persist, particularly in rare diseases, pediatrics and underserved populations. The many promises of pharmacological, technological, and regulatory innovation spark new hope for patients and doctors searching for treatments, and it is therefore essential that progress made translates into the availability of new and improved medicines. We here present our vision for accelerating the path from innovation to safe and effective medicines. Our vision is driven by the continued and transparent collaboration between regulators, academia, industry, patients, and healthcare professionals. Through concrete examples and strategic initiatives, we illustrate how the EMA works with stakeholders to support continuous evolution of regulatory science, contribute to patient‐focused refinements in evidence generation and medicines assessments, and engage in forward‐looking initiatives that monitor and examine innovative developments. The ultimate goal is to future‐proof the regulatory ecosystem and ensure that scientific progress translates into meaningful health outcomes.